Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 250

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 18
Chunk 250
---
                 -             -      
Granted                                65,000       411          
Exercised                             (12,500   )         (79   )
Balance – December 31, 2024            52,500       332          

F-34
----
COSCIENS Biopharma Inc.
 Notes to Consolidated Financial Statements As of December 31, 2024 and 2023 and for the years ended December 31, 2024, 2023 and 2022 
(in thousands of US dollars, except share and per share data and where otherwise noted) 

18.   Shareholders’
          equity   
-------------------
 
Share capital
 
The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.
 
Summary of share capital
 
                                                               Common shares         Amount      
-------------------------------------------------------------------------------------------------
                                                             #                                  $
Balance – January 1, 2022                                             1,833,260         13,389   
Stock options exercised                                                  12,917            107   
Balance – December 31, 2022                                           1,846,177         13,496   
Stock options exercised                                                   1,416             21   
Balance – December 31, 2023                                           1,847,593         13,517   
Deemed issuance of shares to Aeterna shareholders (note 5)            1,213,967          8,485   
Granted                                                                  79,061            484   
Balance – December 31, 2024                                           3,140,621         22,486   
 
As discussed in Note 1, Business Overview, on June 3, 2024, each outstanding Ceapro common share was exchanged for 0.02360 of an Aeterna common share. Accordingly, all common shares, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share exchange.
 
Share-based compensation
 
The Company grants stock options to eligible employees, directors and officers under stock option plans. During the year ended December 31, 2024, the Company granted nil (2023 – 21,712 and 2022 – 10,620) new stock options. The stock options have a term of seven years and will vest over a period